Welcome Back
Join CoinTime
Sign in with email
Sign up with email
Check your inbox
Biocon Biologics
About
Biocon is a fully integrated pure play biosimilars organization, globally engaged in developing high quality affordable biosimilars.
- Bangalore,Karnataka,India
- 5001 - 10000
- https://www.biocon.com/
Details
- Last Funding Type
- Private Equity（PE）
- Last Funding Money Raised
- ₹2.25B
- Industries
- Biotechnology
- Founded date
- Nov 29, 1978
- Number Of Employee
- 5001 - 10000
- Operating Status
- Active
- Legal Name
- Biocon Biologics India Ltd.
Biocon Biologics is a fully-integrated pure-play biosimilars organization globally engaged in developing high-quality, affordable biosimilars aimed at expanding patient access to cutting-edge therapies. It develops and commercializes a differentiated portfolio of novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets, as well as, generic formulations in the U.S. and Europe.The company is driven by a belief that the pharmaceutical industry has a humanitarian responsibility to provide essential drugs to patients who are in need and to do so with the power of innovation.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jan 7, 2021 | Series Unknown | ₹5.55B | 1 |
ADQ
|
— | Detail |
| Nov 9, 2020 | Private Equity（PE） | ₹11.25B | 1 |
Goldman Sachs
|
— | Detail |
| Jul 31, 2020 | Private Equity（PE） | ₹2.25B | 1 |
Tata Capital
|
— | Detail |
| Jan 6, 2020 | Private Equity（PE） | ₹5.36B | 1 |
True North
|
— | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
ADQ
|
Yes | Series Unknown |
|
Goldman Sachs
|
Yes | Private Equity（PE） |
|
Tata Capital
|
Yes | Private Equity（PE） |
|
True North
|
Yes | Private Equity（PE） |
Employee Profiles
Acquisition
Biocon Biologics has acquired 1 organizations. Their most recent acquisition was Viatris Biosimilars on Feb 28, 2021. They acquired Viatris Biosimilars for $3.34B.
|
Date
Company Name
|
Industry | Acquisition Type | Price | |
|---|---|---|---|---|
|
Feb 28, 2021
Viatris Biosimilars
|
Biotechnology | acquisition | $ 3.34B | Detail |
